Danaher Corporation (DHR)
| Market Cap | 142.28B |
| Revenue (ttm) | 23.82B |
| Net Income (ttm) | 3.77B |
| Shares Out | 715.67M |
| EPS (ttm) | 5.16 |
| PE Ratio | 38.55 |
| Forward PE | 25.36 |
| Dividend | $1.28 (0.64%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 5,536,259 |
| Open | 202.05 |
| Previous Close | 201.14 |
| Day's Range | 197.70 - 203.50 |
| 52-Week Range | 171.00 - 281.70 |
| Beta | 0.80 |
| Analysts | Strong Buy |
| Price Target | 265.47 (+33.54%) |
| Earnings Date | Jul 22, 2025 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manuf... [Read more]
Financial Performance
In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for DHR stock is "Strong Buy." The 12-month stock price forecast is $265.47, which is an increase of 33.54% from the latest price.
News
Danaher Appoints Martin Stumpe as Chief Technology and AI Officer
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technol...
Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Boa...
Danaher: High Capex And Low Debt Despite Trump Legislation
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects ...
Danaher Schedules Second Quarter 2025 Earnings Conference Call
WASHINGTON , June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 b...
Prosperity Partners Completes Acquisition of Danaher Attig & Plante
CHICAGO--(BUSINESS WIRE)--Prosperity Partners (“Prosperity”), a Chicago-headquartered tax and accounting business backed by Unity Partners LP (“Unity Partners”), today announced that it has completed ...
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ZenoTOF--At ASMS 2025, SCIEX launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation.
Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AI--SCIEX announces three software ecosystem enhancements at ASMS, supporting the theme that “all science is data science now.”.
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Evocep--SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement.
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid...
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Mike Ryskin - Bank of America Mi...
Danaher to Present at Bank of America Securities Healthcare Conference
WASHINGTON , May 7, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securit...
Danaher Announces Quarterly Dividend
WASHINGTON , May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common sto...
Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity
Danaher Corporation's intrinsic value is estimated at $213 per share, suggesting a 14% upside from the current price of $187, with a 12% margin of safety. Despite revenue growth driven by acquisitions...
Danaher: Q1 Beat Fails To Trigger Guidance Upgrade
Danaher's management appears to be strategically keeping the stock price depressed to complete its share buyback program and capitalize on lower acquisition target valuations. The company delivered be...
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...
Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's Nanoplasmi...
Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript
Danaher Corporation (NYSE:DHR) Q1 2025 Earnings Conference Call April 22, 2025 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President & CEO Matt McGrew - EVP & CFO Conference ...
Danaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times'
Danaher Corp DHR on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the consensus of $5.59 billion.
Danaher beats quarterly profit, expects incremental costs from US tariffs
Danaher beat Wall Street estimates for first-quarter profit on Tuesday, on the back of better-than-expected demand for its respiratory testing kits, and said it expects to incur additional tariff-rela...
Danaher Reports First Quarter 2025 Results
WASHINGTON , April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings we...
3 Wide-Moat Dividend Stars For A Championship Portfolio
I linked investing to baseball, showing how consistency, like the A's Moneyball approach, wins long term. Steady dividend growers and low-volatility stocks outperform, especially in rocky markets. Top...
Danaher Corporation: A Mixed Bag Of Strength And Stagnation
Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent. DHR doesn...
Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins fac...
8 Upcoming Dividend Increases, Including A King
Highlighting eight companies with upcoming dividend increases, four exceeding 10%, and an average increase of 11.4%, median at 9%. My investment strategy focuses on buying, holding, and expanding stak...